Page 37 - Human Use News Today

Operator: [Started Abruptly] … Merck & Co. Q3 Sales and Earnings Conference Call.

Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Call Transcript October 26, 2023 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.13, expectations were $1.95. Operator: [Started Abruptly] … Merck & Co. Q3 Sales and Earnings Conference Call. At this time, all participants are in a listen-only mode until the question-and-answer session of […]

Less than two weeks after getting a thumbs-up from the EMA’s Committee for Medicinal Products for Human Use (CHMP), Santhera Pharmaceutical AG’s vamorolone secured U.S. FDA approval for use in patients, 2 and older, with Duchenne muscular dystrophy (DMD). A first-in-class drug, vamorolone, branded Agamree, is expected to offer a safer alternative to the steroid therapy, which the company has said will remain a foundational treatment of DMD, even with the introduction of gene therapies.

Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;...

Vosoritide is a daily injection for children with achondroplasia who have open epiphyses, given under the skin and administered by a caregiver.

– Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and...

According to Reuters, sales of the COVID-19 antiviral pill jumped 47% to $640 million in the quarter, crushing Wall Street estimates of $120 million.

Geron Corporation , a late-stage clinical biopharmaceutical company, today announced that it will release its third quarter 2023 financial results and business highlights before the market opens on...

Chief Executive John Lee Ka-chiu said the government will set up a preparatory office for the Hong Kong Centre for Medical Products Regulati...

I recently visited India with a central purpose in mind—to strengthen our collective efforts to advance the development and availability of medical products that both our countries and the rest of the world needs.